450 related articles for article (PubMed ID: 27181585)
1. In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.
Fernandes AC; Pedroso RB; de Mello TF; Donatti L; Venazzi EA; Demarchi IG; Aristides SM; Lonardoni MV; Silveira TG
Exp Parasitol; 2016 Aug; 167():83-93. PubMed ID: 27181585
[TBL] [Abstract][Full Text] [Related]
2. Genotypic profiles of Leishmania (Viannia) braziliensis strains from cutaneous leishmaniasis patients and their relationship with the response to meglumine antimoniate treatment: a pilot study.
Gagini T; de Oliveira Schubach A; de Fatima Madeira M; Maria Valete-Rosalino C; Fernandes Pimentel MI; da Silva Pacheco R
Parasite; 2017; 24():34. PubMed ID: 28959938
[TBL] [Abstract][Full Text] [Related]
3. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil.
Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM
Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.
Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G
J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365
[TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology and in vitro evidence suggest that Leishmania braziliensis strain helps determine antimony response among American tegumenary leishmaniasis patients.
Silva SC; Guimarães LH; Silva JA; Magalhães V; Medina L; Queiroz A; Machado PRL; Schriefer A
Acta Trop; 2018 Feb; 178():34-39. PubMed ID: 29042262
[TBL] [Abstract][Full Text] [Related]
6. Leishmania braziliensis isolates differing at the genome level display distinctive features in BALB/c mice.
Indiani de Oliveira C; Teixeira MJ; Teixeira CR; Ramos de Jesus J; Bomura Rosato A; Santa da Silva J; Brodskyn C; Barral-Netto M; Barral A
Microbes Infect; 2004 Sep; 6(11):977-84. PubMed ID: 15345228
[TBL] [Abstract][Full Text] [Related]
7. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
[TBL] [Abstract][Full Text] [Related]
8. Assessment of drug resistance related genes as candidate markers for treatment outcome prediction of cutaneous leishmaniasis in Brazil.
Torres DC; Ribeiro-Alves M; Romero GA; Dávila AM; Cupolillo E
Acta Trop; 2013 May; 126(2):132-41. PubMed ID: 23416123
[TBL] [Abstract][Full Text] [Related]
9. Targeted gene expression profiling in Leishmania braziliensis and Leishmania guyanensis parasites isolated from Brazilian patients with different antimonial treatment outcomes.
Torres DC; Adaui V; Ribeiro-Alves M; Romero GA; Arévalo J; Cupolillo E; Dujardin JC
Infect Genet Evol; 2010 Aug; 10(6):727-33. PubMed ID: 20478409
[TBL] [Abstract][Full Text] [Related]
10. Disseminated cutaneous leishmaniasis caused by Leishmania braziliensis in Southern Brazil.
Membrive NA; Kazuma FJ; Silveira TGV; Teixeira JJV; Reinhold-Castro KR; Teodoro U
Rev Inst Med Trop Sao Paulo; 2017 Jun; 59():e37. PubMed ID: 28591265
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Parasitological Features of Patients with American Cutaneous Leishmaniasis that Did Not Respond to Treatment with Meglumine Antimoniate.
Perez-Franco JE; Cruz-Barrera ML; Robayo ML; Lopez MC; Daza CD; Bedoya A; Mariño ML; Saavedra CH; Echeverry MC
PLoS Negl Trop Dis; 2016 May; 10(5):e0004739. PubMed ID: 27243811
[TBL] [Abstract][Full Text] [Related]
12. In vitro sensitivity of Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis Brazilian isolates to meglumine antimoniate and amphotericin B.
Zauli-Nascimento RC; Miguel DC; Yokoyama-Yasunaka JK; Pereira LI; Pelli de Oliveira MA; Ribeiro-Dias F; Dorta ML; Uliana SR
Trop Med Int Health; 2010 Jan; 15(1):68-76. PubMed ID: 19874570
[TBL] [Abstract][Full Text] [Related]
13. GENOTYPE CHARACTERIZATION OF Leishmania (Viannia) braziliensis ISOLATED FROM HUMAN AND CANINE BIOPSIES WITH AMERICAN CUTANEOUS LEISHMANIASIS.
Ferreira LT; Gomes AH; Pereira-Chioccola VL
Rev Inst Med Trop Sao Paulo; 2015; 57(3):257-62. PubMed ID: 26200968
[TBL] [Abstract][Full Text] [Related]
14. American cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis resistant to meglumine antimoniate, but with good response to pentamidine: a case report.
Pimentel MI; Baptista C; Rubin EF; Vasconcellos Ede C; Lyra MR; Salgueiro Mde M; Saheki MN; Rosalino CM; Madeira Mde F; Silva AF; Confort EM; Schubach Ade O
Rev Soc Bras Med Trop; 2011; 44(2):254-6. PubMed ID: 21552747
[TBL] [Abstract][Full Text] [Related]
15. Leishmania (Viannia) braziliensis genotypes identified in lesions of patients with atypical or typical manifestations of tegumentary leishmaniasis: evaluation by two molecular markers.
Baptista C; Schubach AO; Madeira MF; Leal CA; Pires MQ; Oliveira FS; Conceição-Silva F; Rosalino CM; Salgueiro MM; Pacheco RS
Exp Parasitol; 2009 Apr; 121(4):317-22. PubMed ID: 19135053
[TBL] [Abstract][Full Text] [Related]
16. Responses of Leishmania (Viannia) braziliensis cutaneous infection to N-methylglucamine antimoniate in the rhesus monkey (Macaca mulatta) model.
Teva A; Porrozzi R; Oliveira-Neto MP; Grimaldi GJ
J Parasitol; 2005 Aug; 91(4):976-8. PubMed ID: 17089782
[TBL] [Abstract][Full Text] [Related]
17. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis, the main causative agent of cutaneous leishmaniasis in the New World.
Salay G; Dorta ML; Santos NM; Mortara RA; Brodskyn C; Oliveira CI; Barbiéri CL; Rodrigues MM
Clin Vaccine Immunol; 2007 Sep; 14(9):1173-81. PubMed ID: 17626159
[TBL] [Abstract][Full Text] [Related]
18. Polymerase chain reaction (PCR) is highly sensitive for diagnosis of mucosal leishmaniasis.
Oliveira JG; Novais FO; de Oliveira CI; da Cruz Junior AC; Campos LF; da Rocha AV; Boaventura V; Noronha A; Costa JM; Barral A
Acta Trop; 2005 Apr; 94(1):55-9. PubMed ID: 15777720
[TBL] [Abstract][Full Text] [Related]
19. Leishmaniasis in the major endemic region of Plurinational State of Bolivia: Species identification, phylogeography and drug susceptibility implications.
Bilbao-Ramos P; Dea-Ayuela MA; Cardenas-Alegría O; Salamanca E; Santalla-Vargas JA; Benito C; Flores N; Bolás-Fernández F
Acta Trop; 2017 Dec; 176():150-161. PubMed ID: 28751163
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime.
Netto EM; Marsden PD; Llanos-Cuentas EA; Costa JM; Cuba CC; Barreto AC; Badaró R; Johnson WD; Jones TC
Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
